Search Results 531-540 of 18363 for alopecia
Participants with Grade 2 neuropathy or Grade 2 alopecia are eligible. - Active idiopathic thrombocytopenic purpura. - Stem cell transplant < 100 days prior ...
Note: Treatment-related Grade > 1 alopecia, treatment-related Grade 2 peripheral neuropathy, and treatment-related Grade 2 hypothyroidism on a stable dose ...
Relevant toxicities of prior therapies must have resolved to ≤Grade 1, except for oxaliplatin-related neuropathy or alopecia;; Participant with myocardial ...
Note: Except patients with ≤ Grade 2 neuropathy or any grade of alopecia. Has tumor(s) invading a major vascular structure (e.g., carotid artery) or other ...
In addition, any drug-related toxicity except alopecia should have recovered to Grade 1 or less. Prior therapy with any ERK inhibitor (e.g., LY3214996 ...
Note: Stable chronic conditions (≤ Grade 2) that are not expected to resolve (such as neuropathy, myalgia, alopecia, prior therapy-related endocrinopathies) ...
... alopecia); Patients who are receiving any other investigational agents; Patients with symptomatic central nervous system (CNS) metastases or leptomeningeal ...
... alopecia and endocrinopathies controlled by replacement therapy that must be Grade ≤2 9. Has no serious cardiac dysfunction, left ventricular ejection ...
... Alopecia, lymphopenia, peripheral neuropathy, and ototoxicity ≤Grade 3). Known history of the following conditions: Allergy to gadolinium contrast agents.
... alopecia and other non-clinically significant adverse events (AEs); No active brain metastases or epidural disease; patients with brain metastases previously ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!